$5 million grant supports innovative immunotherapies against blood cancers - The Source wustl.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wustl.edu Daily Mail and Mail on Sunday newspapers.
Researchers at Washington University School of Medicine in St. Louis have received an NCI grant that will provide about $10.9 million to research programs for the development of new therapies for pancreatic ductal adenocarcinoma, the deadliest form of pancreatic cancer.
Researchers at Washington University School of Medicine in St. Louis have received a prestigious grant from the National Cancer Institute of the National Institutes of Health (NIH) to support research and clinical trials aimed at improving therapies for pancreatic cancer.
/PRNewswire/ Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, and the Jaime Leandro Foundation for Therapeutic Cancer Vaccines (JLF),.
The researchers conducted the study in mice with breast cancer and one patient with late-stage pancreatic cancer. The COVID-19 vaccines designed using bits of genetic information that prime our immune systems to recognize and fight off viral infections have become lifesavers in the global fight to end the pandemic. Now, the new research has shown that a similar vaccine approach can be used to create personalized vaccines that program the immune system to attack malignant tumors, including breast and pancreatic cancers. The tailor-made vaccines are designed to target mutated proteins called neoantigens that are unique to a patient’s tumors. Unlike the COVID-19 vaccines made by Moderna and Pfizer/BioNTech that rely on genetic material called mRNA, the personalized cancer vaccines are made using DNA.
Personalized cancer vaccines for breast, pancreatic cancers show promise | The Source wustl.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wustl.edu Daily Mail and Mail on Sunday newspapers.